Torrent Pharmaceuticals Limited

500420

INE685A01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:00:39 2024-05-18 am EDT			5-day change	1st Jan Change
2,705 ^INR	0.00%		+3.88%	+17.36%

May. 14	Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	RE
Apr. 30	Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842	CI

Torrent Pharmaceuticals Limited Appoints Shri Jinesh Shah as Director and Whole Time Director

March 07, 2020 at 07:36 am EST

Torrent Pharmaceuticals Limited appointed Shri Jinesh Shah as Director and Whole Time Director and fixation of remuneration.

Latest news about Torrent Pharmaceuticals Limited

Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	May. 14	RE
Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842	Apr. 30	CI
Torrent Pharmaceuticals Limited Receives Order from Deputy Commissioner State Tax, Special Circle 1, Kunchanapalli, Andhra Pradesh	Apr. 23	CI
Torrent Pharmaceuticals Limited Receives Order Passed by Deputy Commissioner of State Tax, Ropar Division, Punjab Imposing Penalty	Apr. 19	CI
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60	Apr. 08	CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024	Apr. 01	CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director	Feb. 29	CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy	Feb. 08	MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	Feb. 05	MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy	Feb. 05	MT
Torrent Pharmaceuticals Posts Gains in Fiscal Q3 Consolidated Net Profit	Feb. 04	MT
Torrent Pharmaceuticals' Consolidated Profit in Fiscal Q3	Feb. 02	MT
Transcript : Torrent Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 02, 2024	Feb. 02
India's Torrent Pharma posts higher Q3 profit on strong domestic demand	Feb. 02	RE
Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024	Feb. 02	CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 02	CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO	Jan. 23	RE
Torrent Pharmaceuticals Forms New Wholly-Owned Arm in Colombia	Jan. 04	MT
Torrent Pharmaceuticals' Oral Oncology Plant Gets Fives Observations from US FDA	Dec. 11	MT
Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited Enter into Licensing and Supply Agreement to Co-Market, Saroglitazar Mg	Nov. 10	CI
Nomura Adjusts Torrent Pharmaceuticals Price Target to INR2,156 From INR2,199, Keeps at Buy	23-10-25	MT
Torrent Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q2; EPS, Revenue Meet Estimates	23-10-24	MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,040 From INR1,950, Keeps at Hold	23-10-24	MT
Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences	23-10-24	CI
Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative	23-10-23	CI

Chart Torrent Pharmaceuticals Limited

Duration

Period

More charts

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Q4 2024 Earnings Release

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Torrent Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,705 INR

Average target price

2,737 INR

Spread / Average Target

+1.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TORRENT PHARMACEUTICALS LIMITED	+17.36%	10.99B
ELI LILLY AND COMPANY	+34.35%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-3.49%	372B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+9.21%	168B

Other Pharmaceuticals